Fisher unit pursues RNA research

A business unit of Fisher Scientific is teaming up with Alcon Incorporated to use RNA research to develop drugs that can be delivered through the eye.

Dharmacon, the Colorado based business unit of Fisher Biosciences, itself a unit of the Hampton-based corporation, specializes in making products that interfere with RNA, thus silencing disease-causing genes. This RNA interference (RNAi) enables it to target organisms that previously were not treatable by drugs.

Alcon, a German company with headquarters in Dallas, Texas, is known for its eye care products.

Financial terms of the multi-year deal were not disclosed. — NHBR STAFF REPORT